Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 11Head and Neck Neoplasms 5Breast Neoplasms 3Adenocarcinoma of Lung 3Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Gliosarcoma 2Glioblastoma 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma 2Brain Neoplasms 2Adenocarcinoma Of Esophagus 2Urinary Bladder Neoplasms 1Untreated Childhood Anaplastic Astrocytoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Salivary Gland Neoplasms 1Recurrence 1Pleural Effusion, Malignant 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Lymphoid Interstitial Pneumonia 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1

Interventions

Paclitaxel 57Carboplatin 51Bevacizumab 41Taxes 28liposomal doxorubicin 21Gemcitabine 19Immunoglobulin G 17Disulfides 17pembrolizumab 15Topotecan 12rucaparib 10Cyclophosphamide 9Cisplatin 9Docetaxel 8olaparib 7Doxorubicin 7pazopanib 6mirvetuximab soravtansine 6cediranib 6Nivolumab 6Magnetic Resonance Spectroscopy 6Specimen Handling 5sargramostim 4niraparib 4Surgical Procedures, Operative 4Drug Therapy 4Cytoreduction Surgical Procedures 4Albumin-Bound Paclitaxel 4veliparib 3fludarabine phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Fallopian Tube Neoplasms × Gefitinib × Clear all
NCT00317772 2022-02-07

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
19 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡